

## **Annual Management Report of Fund Performance**

*For the Year Ended March 31, 2024*

*This Annual Management Report of Fund Performance contains financial highlights but does not contain the complete annual financial statements of the investment fund. You may obtain a copy of the annual financial statements, at no cost, by calling 1-888-746-6344 (1-800-661-4578 if you live in Quebec) or by writing to us at 447 Portage Avenue, Winnipeg, Manitoba, R3B 3H5 (2001, boulevard Robert-Bourassa, bureau 2000, Montreal (Quebec), H3A 2A6 if you live in Quebec), or by visiting the SEDAR+ website at [www.sedarplus.ca](http://www.sedarplus.ca).*

*Securityholders may also contact us using one of these methods to request a copy of the investment fund's interim financial report, proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure. For more information, please refer to the Fund's Simplified Prospectus and Fund Facts, which may also be obtained, at no cost, using any of the methods outlined above.*

*For the Fund's current net asset values per security and for more recent information on general market events, please visit our website at [www.ig.ca](http://www.ig.ca).*

*References to "Consultant" or "Consultants" mean "Representative" or "Representatives" in Quebec.*

### **A NOTE ON FORWARD-LOOKING STATEMENTS**

*This report may contain forward-looking statements that reflect our current expectations or forecasts of future events. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", "preliminary", "typical" and other similar expressions. In addition, these statements may relate to future corporate actions, future financial performance of a fund or a security and their future investment strategies and prospects. Forward-looking statements are inherently subject to, among other things, risks, uncertainties and assumptions that could cause actual events, results, performance or prospects to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and assumptions include, without limitation, general economic, political and market factors in North America and internationally, interest and foreign exchange rates, the volatility of global equity and capital markets, business competition, technological change, changes in government regulations, changes in securities laws and regulations, changes in tax laws, unexpected judicial or regulatory proceedings, catastrophic events, outbreaks of disease or pandemics (such as COVID-19), and the ability of manager to attract or retain key employees. The foregoing list of important risks, uncertainties and assumptions is not exhaustive. Please consider these and other factors carefully and do not place undue reliance on forward-looking statements.*

*The forward-looking information contained in this report is current only as of the date of this report. There should not be an expectation that such information will in all circumstances be updated, supplemented or revised whether as a result of new information, changing circumstances, future events or otherwise.*

# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024

## Management Discussion of Fund Performance

June 6, 2024

This Management Discussion of Fund Performance presents the portfolio management team's view on the significant factors and developments that have affected the Fund's performance and outlook in the year ended March 31, 2024 (the "period"). If the Fund was established during the period, "period" represents the period since inception.

In this report, "IGIM" and "the Manager" refer to I.G. Investment Management, Ltd., the manager of the Fund. In addition, net asset value ("NAV") refers to the value of the Fund as calculated for transaction purposes, on which the discussion of Fund performance is based.

Please read *A Note on Forward-Looking Statements* on the first page of this document.

On February 16, 2023, the IG Wealth Management Funds' Independent Review Committee approved a proposal to wind up Investors Group Corporate Class Inc. and merge its suite of Corporate Class funds into corresponding trust fund equivalents because it was in a taxable position. As a result, investors holding securities of IG Mackenzie Global Health Care Class (the "Predecessor Fund") were merged into the corresponding series of the Fund on a tax-deferred basis on May 19, 2023. The fees, the investment objective and strategies, and the portfolio management team of the Fund are substantially similar to those of the Predecessor Fund. Consequently the information in this report is presented as if the Fund had existed since the inception of the Predecessor Fund.

### Investment Objective and Strategies

The Fund aims to provide long-term capital growth by investing in the common shares of global corporations engaged in the development, production or distribution of products and services related to the treatment or prevention of medical diseases or other medical related problems.

### Risk

The risks of the Fund remain as discussed in the Fund's Simplified Prospectus.

The Fund is suitable for long-term investors looking for capital growth who intend to hold this investment as one component of a diversified investment portfolio and who have a medium tolerance for risk.

### Results of Operations

#### Investment Performance

The performance of all series in the current and previous periods is shown in the *Past Performance* section of the report. Performance will vary by series primarily because fees and expenses differ between series, or because securities of a series were not issued and outstanding for the entire reporting period. Please refer to the *Fund Formation and Series Information* section of this report for the varying management and administration fees payable by each series. The following comparison to market indices is intended to help investors understand the Fund's performance relative to the general performance of the markets. However, the Fund's mandate may be different from that of the indices shown.

For the year ended March 31, 2024, the Series F securities returned 14.3% (after deducting fees and expenses paid by the Fund). In comparison, the Fund's broad-based index, the MSCI World (Net) Index, returned 25.2% and the Fund's narrow index, the MSCI World Health Care (Net) Index, returned 13.5%. Given the Fund's mandate, the narrow index has been included as a more meaningful comparison.

Global equities rose over the period as central banks slowed the pace of interest rate increases. The global economy was resilient, and employment remained strong. Global equity markets experienced increasing valuation multiples, although gains in the U.S. equity market came largely from a small number of mega-capitalization stocks. Inflation slowed but remained slightly above central bank targets.

Within the MSCI World Health Care (Net) Index, Israel, Denmark and Belgium were the strongest-performing markets in Canadian dollar terms, while Germany, Finland and New Zealand were the weakest. Among industries, pharmaceuticals, health care equipment and supplies, and health care providers and services were the strongest performers, while life sciences tools and services, health care technology and biotechnology were the weakest.

The Fund underperformed the broad-based index because of its focus on the health care sector, which underperformed the broader market over the period.

The Fund outperformed the narrow index, with stock selection in the United States and underweight exposure to Germany contributing to performance. In industry terms, stock selection in health care providers and services and in pharmaceuticals contributed to performance. Stock selection in the health care equipment and supplies industry detracted from performance.

### Net Assets

The Fund's net assets increased by 3.9% during the period to \$333.1 million. This change was composed primarily of \$41.6 million in net income (including any interest and/or dividend income) from investment performance, after deducting fees and expenses, and a decrease of \$29.1 million due to net securityholder activity (including sales, redemptions and cash distributions).

### Fees and Expenses

The management expense ratio ("MER") for each series during the year ended March 31, 2024, was generally similar to the MER for the year ended March 31, 2023. Total expenses paid vary from period to period mainly as a result of changes in average assets in each series. The MERs for all series are presented in the *Financial Highlights* section of this report.

### Recent Developments

The portfolio management team takes a quantitative approach to stock selection that employs systematic factor analysis. Measures such as earnings growth, price-earnings ratio, free cash flow variability and industry sales trends are used to rank global health care stocks according to expected returns. As such, the team does not generate market expectations or position the Fund's portfolio according to economic forecasts.

### Other Developments

With the approval of the IG Wealth Management Funds Independent Review Committee, the Predecessor Fund merged into the Fund on May 19, 2023.

Effective May 3, 2024, Series A was redesignated as Series B; and effective May 10, 2024, Series J DSC was redesignated as Series J NL.

# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024

## Related Party Transactions

I.G. Investment Management, Ltd. is the Manager, Trustee and Portfolio Advisor of the Fund. The Fund is offered through the Consultants of Investors Group Financial Services Inc. and Investors Group Securities Inc., together referred to as the Distributors. The Manager, Portfolio Advisor, Distributors and Trustee are, indirectly, wholly owned subsidiaries of IGM Financial Inc.

The following sub-advisor provided investment services to the Fund:

- Mackenzie Financial Corporation

Mackenzie Financial Corporation is a wholly owned subsidiary of IGM Financial Inc.

The Fund paid a management fee to the Manager and Portfolio Advisor for management and portfolio advisory services (see *Management Fees*).

The Fund also paid the Manager an administration fee and in exchange the Manager paid the operating costs and expenses of the Fund, except for certain specified costs.

The Fund paid the Distributors a service fee as compensation for providing or arranging for the provision of services to the Fund, including the issue or allotment of securities.

The Trustee is responsible for the overall direction of the affairs of the Fund. The Fund paid the Trustee a fee for its services.

See *Fund Formation and Series Information* for the annual rates paid by each series (as a percentage of average net assets) for these fees.

Securityholders in Series F also pay an advisory fee directly to the Distributors. This fee is not included in the Fund's expenses.

The Manager relied on an approval issued by the IG Wealth Management Funds Independent Review Committee to proceed with the merger of the Predecessor Fund into the Fund on May 19, 2023.

## Past Performance




The Fund's performance information assumes all distributions made by the Fund in the periods presented are reinvested in additional securities of the relevant series of the Fund. The performance information does not take into account sales, redemption, distribution or other optional charges, or income taxes payable by any investor that would have reduced returns or performance. The past performance of the Fund is not necessarily an indication of how it will perform in the future.

If you hold this Fund outside of a registered plan, income and capital gains distributions paid to you increase your income for tax purposes whether paid to you in cash or reinvested in additional securities of the Fund. The amount of reinvested taxable distributions is added to the adjusted cost base of the securities that you own. This would decrease your capital gain or increase your capital loss when you later redeem from the Fund, thereby ensuring that you are not taxed on this amount again. Please consult your tax advisor regarding your personal tax situation.

The past performance before May 19, 2023, is based on the performance of the applicable series of the Predecessor Fund, which was merged into the corresponding series of the Fund on that date.



## Year-by-Year Returns

The following bar charts present the performance of each series of the Fund for each of the fiscal periods shown. The charts show, in percentage terms, how much an investment made on the first day of each fiscal period, or on the series inception or reinstatement date, as applicable, would have increased or decreased by the last day of the fiscal period presented. Series inception or reinstatement dates can be found under *Fund Formation and Series Information*.



# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024



## Annual Compound Returns

The following table compares the historical annual compound total returns for each series of the Fund with the relevant index or indices shown below for each of the periods ended March 31, 2024. Investors cannot invest in an index without incurring fees, expenses and commissions, which are not reflected in these performance figures.

All index returns are calculated in Canadian with U.S. dollars on a total return basis, meaning that all dividend payments, interest income accruals and interest payments are reinvested.

Percentage Return: <sup>1</sup>	1 Yr	3 Yr	5 Yr	10 Yr	Since Inception <sup>2</sup>
Series A	12.6	9.2	9.6	9.2	n/a
Series B	12.6	9.2	9.6	9.1	n/a
Series F	14.3	10.8	11.3	10.8	n/a
Series J DSC	12.9	9.5	9.9	9.5	n/a
Series J NL	12.9	9.5	9.9	9.4	n/a
MSCI World (Net) Index*	25.2	11.3	12.4	11.6	n/a
MSCI World Health Care (Net) Index	13.5	10.6	10.6	11.4	n/a

\* Broad-based index

The MSCI World (Net) Index represents large- and mid-cap equity performance across 23 developed markets. Net total returns are calculated after the deduction of withholding tax from the foreign income and dividends of its constituents.

The MSCI World Health Care (Net) Index represents large- and mid-cap equity performance across 23 developed markets. All securities in the index are classified in the health care sector as per the Global Industry Classification Standard ("GICS"). Net total returns are calculated after the deduction of withholding tax from the foreign income and dividends of its constituents.

- (1) The percentage return differs for each series because the management fee rate and expenses differ for each series.
- (2) The return since inception for each series will differ when the inception date differs and is only provided when a series has been active for a period of less than 10 years.

# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024

## Summary of Investment Portfolio at March 31, 2024

PORTFOLIO ALLOCATION	% OF NAV
Equities	98.3
Exchange-traded funds	1.0
Cash and cash equivalents	0.5
Other assets (liabilities)	0.2

REGIONAL ALLOCATION	% OF NAV
United States	76.0
Switzerland	6.2
Japan	5.2
United Kingdom	5.0
Denmark	4.7
France	0.5
Australia	0.5
Germany	0.5
Cash and cash equivalents	0.5
Israel	0.4
Italy	0.2
Other assets (liabilities)	0.2
Sweden	0.1

SECTOR ALLOCATION	% OF NAV
Pharmaceuticals	42.1
Health care equipment and supplies	17.1
Health care providers and services	17.0
Biotechnology	13.0
Life sciences tools and services	9.0
Exchange-traded funds	1.0
Cash and cash equivalents	0.5
Other assets (liabilities)	0.2
Commercial services and supplies	0.1

TOP 25 POSITIONS	% OF NAV
Issuer	
Eli Lilly and Co.	7.2
Johnson & Johnson	5.8
UnitedHealth Group Inc.	5.2
AbbVie Inc.	5.1
Novo Nordisk AS	4.5
Thermo Fisher Scientific Inc.	3.8
Roche Holding AG	3.5
Merck & Co. Inc.	3.5
Amgen Inc.	2.9
Cigna Corp.	2.5
Medtronic PLC	2.5
Bristol-Myers Squibb Co.	2.4
CVS Health Corp.	2.3
Gilead Sciences Inc.	2.1
GSK PLC	2.1
Stryker Corp.	2.0
AstraZeneca PLC	1.9
Novartis AG	1.9
Abbott Laboratories	1.8
IQVIA Holdings Inc.	1.6
Agilent Technologies Inc.	1.6
Cencora Inc.	1.5
Danaher Corp.	1.5
Centene Corp.	1.5
Hoya Corp.	1.5

Top long positions as a percentage  
of total net asset value

72.2

*The Fund held no short positions at the end of the period.*

*The investments and percentages may have changed since March 31, 2024, due to the ongoing portfolio transactions of the Fund. Quarterly updates of holdings are available within 60 days of the end of each quarter except for March 31, the Fund's fiscal year-end, when they are available within 90 days.*

# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024

## Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for each of the fiscal periods presented below. If during the period a series was established or reinstated, "period" represents the period from inception or reinstatement to the end of that fiscal period. Series inception or reinstatement dates can be found under *Fund Formation and Series Information*.

The financial information before May 19, 2023, is based on the performance of the applicable series of the Predecessor Fund, which was merged into the corresponding series of the Fund on that date.

### THE FUND'S NET ASSETS PER SECURITY (\$)¹

Series A	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
<b>Net assets, beginning of period</b>	37.63	37.49	32.97	29.64	27.08
<b>Increase (decrease) from operations:</b>					
Total revenue	0.72	0.80	0.57	0.52	0.70
Total expenses	(1.12)	(1.05)	(1.03)	(0.94)	(0.82)
Realized gains (losses) for the period	8.25	0.65	2.22	3.10	3.23
Unrealized gains (losses) for the period	(3.35)	(0.07)	3.46	1.07	(0.55)
<b>Total increase (decrease) from operations²</b>	4.50	0.33	5.22	3.75	2.56
<b>Distributions:</b>					
From net investment income (excluding Canadian dividends)	-	-	-	-	-
From Canadian dividends	-	-	-	-	-
From capital gains	-	(0.19)	(0.28)	-	-
Return of capital	-	-	-	-	-
<b>Total annual distributions³</b>	-	(0.19)	(0.28)	-	-
<b>Net assets, end of period</b>	42.35	37.63	37.49	32.97	29.64
<b>Series B</b>	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
<b>Net assets, beginning of period</b>	37.04	36.91	32.46	29.18	26.65
<b>Increase (decrease) from operations:</b>					
Total revenue	0.70	0.79	0.56	0.52	0.68
Total expenses	(1.11)	(1.04)	(1.01)	(0.92)	(0.79)
Realized gains (losses) for the period	8.23	0.68	2.17	2.75	3.18
Unrealized gains (losses) for the period	(3.30)	(0.06)	3.41	1.05	(0.54)
<b>Total increase (decrease) from operations²</b>	4.52	0.37	5.13	3.40	2.53
<b>Distributions:</b>					
From net investment income (excluding Canadian dividends)	-	-	-	-	-
From Canadian dividends	-	-	-	-	-
From capital gains	-	(0.19)	(0.28)	-	-
Return of capital	-	-	-	-	-
<b>Total annual distributions³</b>	-	(0.19)	(0.28)	-	-
<b>Net assets, end of period</b>	41.69	37.04	36.91	32.46	29.18

Series F	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
<b>Net assets, beginning of period</b>	26.15	26.10	22.96	20.46	18.57
<b>Increase (decrease) from operations:</b>					
Total revenue	0.50	0.56	0.40	0.36	0.48
Total expenses	(0.37)	(0.37)	(0.33)	(0.30)	(0.26)
Realized gains (losses) for the period	5.85	0.49	1.09	1.11	2.23
Unrealized gains (losses) for the period	(2.34)	(0.05)	2.43	0.73	(0.37)
<b>Total increase (decrease) from operations²</b>	3.64	0.63	3.59	1.90	2.08
<b>Distributions:</b>					
From net investment income (excluding Canadian dividends)	(0.12)	-	-	-	-
From Canadian dividends	(0.04)	(0.11)	(0.13)	(0.15)	(0.18)
From capital gains	-	(0.44)	(0.48)	-	-
Return of capital	-	-	-	-	-
<b>Total annual distributions³</b>	(0.16)	(0.55)	(0.61)	(0.15)	(0.18)
<b>Net assets, end of period</b>	29.70	26.15	26.10	22.96	20.46
<b>Series J DSC</b>	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
<b>Net assets, beginning of period</b>	33.75	33.63	29.58	26.52	24.17
<b>Increase (decrease) from operations:</b>					
Total revenue	0.64	0.72	0.51	0.47	0.62
Total expenses	(0.90)	(0.86)	(0.84)	(0.76)	(0.66)
Realized gains (losses) for the period	7.28	0.28	2.29	2.66	2.89
Unrealized gains (losses) for the period	(3.01)	(0.06)	3.11	0.96	(0.49)
<b>Total increase (decrease) from operations²</b>	4.01	0.08	5.07	3.33	2.36
<b>Distributions:</b>					
From net investment income (excluding Canadian dividends)	-	-	-	-	-
From Canadian dividends	-	-	-	-	-
From capital gains	-	(0.27)	(0.34)	-	-
Return of capital	-	-	-	-	-
<b>Total annual distributions³</b>	-	(0.27)	(0.34)	-	-
<b>Net assets, end of period</b>	38.10	33.75	33.63	29.58	26.52

- (1) These calculations are prescribed by securities regulations and are not intended to be a reconciliation between opening and closing net assets per security. This information is derived from the Fund's audited annual financial statements. The net assets per security presented in the financial statements may differ from the net asset value per security calculated for fund pricing purposes. An explanation of these differences, if any, can be found in the *Notes to Financial Statements*.
- (2) Net assets and distributions are based on the actual number of securities outstanding at the relevant time. The increase/decrease from operations is based on the weighted average number of securities outstanding over the fiscal period.
- (3) Distributions were paid in cash, reinvested in additional securities of the Fund, or both.

# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024

## THE FUND'S NET ASSETS PER SECURITY (\$) <sup>1</sup> (cont'd)

Series J NL	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
<b>Net assets, beginning of period</b>	<b>33.66</b>	33.53	29.50	26.44	24.09
<b>Increase (decrease) from operations:</b>					
Total revenue	0.64	0.71	0.51	0.47	0.62
Total expenses	(0.91)	(0.86)	(0.83)	(0.76)	(0.65)
Realized gains (losses) for the period	7.42	0.09	2.36	2.33	2.88
Unrealized gains (losses) for the period	(3.00)	(0.06)	3.10	0.95	(0.49)
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>4.15</b>	(0.12)	5.14	2.99	2.36
<b>Distributions:</b>					
From net investment income (excluding Canadian dividends)	-	-	-	-	-
From Canadian dividends	-	-	-	-	-
From capital gains	-	(0.26)	(0.34)	-	-
Return of capital	-	-	-	-	-
<b>Total annual distributions<sup>3</sup></b>	<b>-</b>	(0.26)	(0.34)	-	-
<b>Net assets, end of period</b>	<b>37.98</b>	33.66	33.53	29.50	26.44

## RATIOS AND SUPPLEMENTAL DATA

Series A	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
Total net asset value (\$000) <sup>1</sup>	25,581	28,376	40,061	54,447	72,008
Securities outstanding (000) <sup>1</sup>	604	754	1,069	1,651	2,429
Management expense ratio (%) <sup>2</sup>	2.75	2.76	2.79	2.79	2.79
Management expense ratio before waivers or absorptions (%) <sup>2</sup>	2.75	2.76	2.79	2.79	2.79
Trading expense ratio (%) <sup>3</sup>	0.15	0.08	0.07	0.08	0.11
Portfolio turnover rate (%) <sup>4</sup>	76.06	37.68	46.31	74.60	91.61
Net asset value per security (\$)	42.36	37.63	37.49	32.97	29.64
Series B	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
Total net asset value (\$000) <sup>1</sup>	17,085	16,950	22,904	29,732	32,764
Securities outstanding (000) <sup>1</sup>	410	458	621	916	1,123
Management expense ratio (%) <sup>2</sup>	2.75	2.76	2.78	2.77	2.76
Management expense ratio before waivers or absorptions (%) <sup>2</sup>	2.75	2.76	2.78	2.77	2.76
Trading expense ratio (%) <sup>3</sup>	0.15	0.08	0.07	0.08	0.11
Portfolio turnover rate (%) <sup>4</sup>	76.06	37.68	46.31	74.60	91.61
Net asset value per security (\$)	41.70	37.04	36.91	32.46	29.18
Series F	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
Total net asset value (\$000) <sup>1</sup>	276,966	258,738	241,097	173,235	70,169
Securities outstanding (000) <sup>1</sup>	9,323	9,893	9,239	7,546	3,430
Management expense ratio (%) <sup>2</sup>	1.20	1.21	1.25	1.25	1.24
Management expense ratio before waivers or absorptions (%) <sup>2</sup>	1.20	1.21	1.25	1.25	1.24
Trading expense ratio (%) <sup>3</sup>	0.15	0.08	0.07	0.08	0.11
Portfolio turnover rate (%) <sup>4</sup>	76.06	37.68	46.31	74.60	91.61
Net asset value per security (\$)	29.71	26.15	26.10	22.96	20.46

(1) This information is provided as at the end of the fiscal period shown.

(2) Management expense ratio ("MER") is based on total expenses, excluding commissions and other portfolio transaction costs, income taxes and withholding taxes, for the stated period and is expressed as an annualized percentage of daily average net assets during the period, except as noted. In the period a series is established, the MER is annualized from the date of inception to the end of the period. Where the Fund directly invests in securities of another fund (including exchange-traded funds or "ETFs"), the MERs presented for the Fund include the portion of MERs of the other fund(s) attributable to this investment. Any income distributions received from ETFs managed by affiliates of the Manager, with the intention of offsetting fees paid within those ETFs but which are not considered to be duplicative fees under regulatory requirements, are treated as waived expenses for MER purposes. The Manager may waive or absorb operating expenses at its discretion and stop waiving or absorbing such expenses at any time without notice.

(3) The trading expense ratio ("TER") represents total commissions and other portfolio transaction costs incurred as an annualized percentage of daily average net assets during the period. Where the Fund invests in securities of another fund (including ETFs), the TERs presented for the Fund include the portion of TERs of the other fund(s) attributable to this investment.

(4) The Fund's portfolio turnover rate indicates how actively the Fund's portfolio advisor manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher the Fund's portfolio turnover rate in a period, the greater the trading costs payable by the Fund in the period, and the greater the chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high turnover rate and the performance of a fund. The portfolio turnover rate is not provided when the Fund is less than one year old. The value of any trades to realign the Fund's portfolio after a fund merger, if any, is excluded from the portfolio turnover rate.

# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024

## RATIOS AND SUPPLEMENTAL DATA (cont'd)

	Mar. 31 2024	Mar. 31 2023	Mar. 31 2022	Mar. 31 2021	Mar. 31 2020
<b>Series J DSC</b>					
Total net asset value (\$000) <sup>1</sup>	8,649	10,843	13,897	27,049	35,375
Securities outstanding (000) <sup>1</sup>	227	321	413	914	1,334
Management expense ratio (%) <sup>2</sup>	2.47	2.49	2.52	2.52	2.52
Management expense ratio before waivers or absorptions (%) <sup>2</sup>	2.47	2.49	2.52	2.52	2.52
Trading expense ratio (%) <sup>3</sup>	0.15	0.08	0.07	0.08	0.11
Portfolio turnover rate (%) <sup>4</sup>	76.06	37.68	46.31	74.60	91.61
Net asset value per security (\$)	38.10	33.75	33.63	29.58	26.52
<b>Series J NL</b>					
Total net asset value (\$000) <sup>1</sup>	4,864	5,745	5,875	11,124	12,133
Securities outstanding (000) <sup>1</sup>	128	171	175	377	459
Management expense ratio (%) <sup>2</sup>	2.47	2.49	2.52	2.51	2.50
Management expense ratio before waivers or absorptions (%) <sup>2</sup>	2.47	2.49	2.52	2.51	2.50
Trading expense ratio (%) <sup>3</sup>	0.15	0.08	0.07	0.08	0.11
Portfolio turnover rate (%) <sup>4</sup>	76.06	37.68	46.31	74.60	91.61
Net asset value per security (\$)	37.99	33.66	33.53	29.50	26.44

## Management Fees

The Fund pays a management fee, and this fee, paid by each series, is calculated as a percentage of the net asset value of the series at the close of each business day (see *Fund Formation and Series Information* for rates payable by each series). Generally, management fees pay the costs incurred to provide investment advisory and management services, as well as distribution-related services provided by the Distributors.

However, in the case of Series F, securityholders pay the Distributor an advisory fee (separate from the management fee) directly. Therefore, the management fee in that series is used for investment advisory and management services only.

For all other retail series (i.e. those that exclude Series R, P and S, if issued), approximately 59% of management fees paid during the period was used for investment advisory and management services, and approximately 41% related to distribution-related services. This may vary by series.



# IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE | For the Year Ended March 31, 2024

## Fund Formation and Series Information

Date of Formation: February 27, 2023

Series	Inception/ Reinstatement Date	Management fee (%)	Service fee (%)	Administration fee (%)	Trustee fee (%)
Series A	October 24, 2002	1.95	0.30	0.18	0.05
Series B	October 24, 2002	1.95	0.30	0.18	0.05
Series F	July 12, 2013	0.85	–	0.18	0.05
Series J DSC	July 13, 2012	1.70	0.30	0.18	0.05
Series J NL	July 13, 2012	1.70	0.30	0.18	0.05

The fee rates in the table above are rounded to two decimals.

These are the inception dates of the applicable series of the Predecessor Fund.

Until June 28, 2022, the annual management fee rates were as follows: Series A and B: 2.00%; Series F: 0.90%; Series J DSC and J NL: 1.75%.

Effective May 3, 2024, Series A was redesignated as Series B; and effective May 10, 2024, Series J DSC was redesignated as Series J NL.